CD4 and chronic myelogenous leukemia, BCR-ABL1 positive: In summary, CML-RAE-1γ-Dex were demonstrated to simultaneously activate multiple immune cell types such as NK cells and CD4+ and CD8+ T lymphocytes, through the NKG2D/NKG2D-L (RAE-1γ) pathway, which led to anti-CML efficacy in vitro and in vivo.